|
Nasopharyngeal Neoplasms
|
0.400 |
GeneticVariation
|
group |
GWASCAT |
A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry.
|
26545403 |
2016 |
|
Nasopharyngeal Neoplasms
|
0.400 |
GeneticVariation
|
group |
GWASCAT |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
Nasopharyngeal Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
melanoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
TROY is expressed in 2/2 primary melanoma cells and 45/45 melanoma tissue samples (p < 0.0001).
|
17187358 |
2007 |
|
melanoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
TROY is expressed in 2/2 primary melanoma cells and 45/45 melanoma tissue samples (p < 0.0001).
|
17187358 |
2007 |
|
melanoma
|
0.310 |
Biomarker
|
disease |
LHGDN |
TROY is expressed in 2/2 primary melanoma cells and 45/45 melanoma tissue samples (p < 0.0001).
|
17187358 |
2007 |
|
Cancer of Nasopharynx
|
0.300 |
Biomarker
|
disease |
CTD_human |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
Nasopharyngeal carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Our data reveal that gain of function of TNFRSF19 in NPC represents a mechanism by which tumor cells evade the growth-inhibitory action of TGFβ.<b>Significance:</b><i>TNFRSF19</i>, a susceptibility gene for nasopharyngeal carcinoma and other cancers, functions as a potent inhibitor of the TGFβ signaling pathway.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/13/3469/F1.large.jpg <i></i>.
|
29735548 |
2018 |
|
Nasopharyngeal carcinoma
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Our results also provide support for associations reported from published NPC GWAS-rs6774494 (P = 1.5 × 10(-12); located in the MECOM gene region), rs9510787 (P = 5.0 × 10(-10); located in the TNFRSF19 gene region), and rs1412829/rs4977756/rs1063192 (P = 2.8 × 10(-8), P = 7.0 × 10(-7), and P = 8.4 × 10(-7), respectively; located in the CDKN2A/B gene region).
|
26545403 |
2016 |
|
Nasopharyngeal carcinoma
|
0.130 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
Nasopharyngeal carcinoma
|
0.130 |
Biomarker
|
disease |
BEFREE |
Our findings provide new insights into the pathogenesis of NPC by highlighting the involvement of pathways related to TNFRSF19 and MDS1-EVI1 in addition to HLA molecules.
|
20512145 |
2010 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Joint Association Analysis Identified 18 New Loci for Bone Mineral Density.
|
30690781 |
2019 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion.
|
29117939 |
2018 |
|
Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that TROY (TNFRSF19) plays an important role in glioblastoma cell invasion and therapeutic resistance.
|
30219706 |
2018 |
|
Adult Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion.
|
29117939 |
2018 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that TROY (TNFRSF19) plays an important role in glioblastoma cell invasion and therapeutic resistance.
|
30219706 |
2018 |
|
Childhood Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that TROY (TNFRSF19) plays an important role in glioblastoma cell invasion and therapeutic resistance.
|
30219706 |
2018 |
|
Childhood Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion.
|
29117939 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion.
|
29117939 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Here, we identified PDZ-RhoGEF as a binding partner for TROY that potentiated TROY-induced nuclear factor kappa B activation which is necessary for both cell invasion and survival.
|
30219706 |
2018 |
|
Glioblastoma Multiforme
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
TROY expression significantly increases the capacity of EGF to stimulate glioblastoma cell invasion, whereas depletion of TROY expression blocks EGF stimulation of glioblastoma cell invasion.
|
29117939 |
2018 |
|
Glioblastoma Multiforme
|
0.040 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated that TROY (TNFRSF19) plays an important role in glioblastoma cell invasion and therapeutic resistance.
|
30219706 |
2018 |
|
Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings position aberrant expression and/or signaling by TROY as a contributor to the dispersion of glioblastoma cells and therapeutic resistance.
|
23699535 |
2013 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings position aberrant expression and/or signaling by TROY as a contributor to the dispersion of glioblastoma cells and therapeutic resistance.
|
23699535 |
2013 |